Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesVascular Endothelial Growth Factor Signaling is Required for the Behavioral Actions of Antidepressant Treatment: Pharmacological and Cellular Characterization
Neuropsychopharmacology, 06/25/09
Greene J et al. - These studies show that VEGF is necessary for the behavioral effects of the SSRI fluoxetine, as well as norepinephrine selective reuptake inhibitor, and that these effects may be mediated by 5-HT1A receptors located on neurons and endothelial cells.
Dr RS Duman, 06/25/09
| This paper extends previous work on the role of VEGF in the neurogenic and behavioral actions of antidepressant treatments. Studies are currently underway to determine the cellular mechanisms underlying the actions of VEGF, and association VEGF polymorphisms in mood disorder patients, work that could lead to novel therapeutic interventions. |
Today in Neuro/Psych pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents
JAMA, 10/29/09
Outcome of intracerebral haemorrhage patients pre-treated with statins
European Journal of Neurology, 11/17/09
Statin use and neurologic morbidity after coronary artery bypass grafting. A cohort study
Neurology, 11/16/09
Sponsor
Article Search
Sponsor